Arrowhead Research | ARWR - Operating Profit


Arrowhead Research reported $40.81M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025